Relative Contraindications (Use with Caution): Severe renal impairment (eGFR below 30), diabetic retinopathy, severe gastroparesis, history of gallbladder disease, concurrent use of insulin or sulfonylureas (hypoglycaemia risk)
Thyroid cancer Taking semaglutide can increase your risk of thyroid C-cell tumors, including medullary thyroid carcinoma, and multiple endocrine neoplasia type 2 (MEN 2)
Seek medical attention if the side effects become intolerable
Il semaglutide orale trasporta la stessa molecola del farmaco iniettabile attraverso la parete dello stomaco grazie a un eccipiente speciale chiamato SNAC (sale dellacido salcaprozato), che aumenta temporaneamente il pH locale e facilita il passaggio transcellulare
The Regulatory Context: What the Industry Landscape Means for Prospective Patients The compounded telehealth GLP-1 industry has faced increasing regulatory attention since 2025, and that trend has only accelerated
"We continuously collect safety data on our marketed medicines and work closely with the authorities to ensure patient safety